An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.

Studied

Narrative review integrating metabolic, inflammatory, immune and antifibrotic treatment targets for non-alcoholic steatohepatitis and fibrosis.

Who / model

The abstract describes pathways and candidate therapies rather than a defined participant group, species, sample size, intervention, comparator or follow-up period.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

The review maps hormonal agonists, immune targets and stellate-cell pathways onto inflammation and fibrosis. It notes that fibrosis is reversible, but does not report a tested treatment effect.

Limits

This is a mechanistic review, not a comparative clinical trial. The authors identify disease heterogeneity and divergent drivers as obstacles to finding broadly effective treatments; no author-stated methodological limitation appears in the abstract.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary